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School of Medicine, Richmond, VA, USAExposure to a sedentary lifestyle, fat-rich and ﬁber-poor diets,
positive caloric imbalance and an extended life disrupt the met-
abolic homeostasis causing non-alcoholic fatty liver disease. A
subset of patients with this emerging public health problem
may develop non-alcoholic steatohepatitis (NASH) and progress
to cirrhosis and liver cancer [1]. Understanding the molecular
mechanisms promoting liver injury in NASH is not only of bio-
medical and public health interest, but also key to develop new
avenues for speciﬁc treatment interventions. In this Snapshot
article, we will outline current evolving concepts of signaling cas-
cades that may be linked to liver injury in NASH. It is important
to acknowledge that a signiﬁcant amount of information has been
obtained from in vitro and animal studies that may not entirely
reﬂect the situation in the liver of patients with NASH. In addi-
tion, multiple pathways leading to apoptosis may be operational
in NASH patients at the same time, but the relative contribution
of each one is unknown. Nevertheless, targeting apoptotic path-
ways in NASH may represent a viable therapeutic strategy partic-
ularly in the context of acute liver injury augmented by fatty liver
or in the setting of transplantation using highly steatotic donor
livers.
Major sources of hepatic saturated fatty acids (SFAs) are adi-
pose tissue, diet, and de novo lipogenesis from glucose. Under
physiological conditions, SFA are transported to mitochondria
for b-oxidation or esteriﬁed for either excretion in very low den-
sity lipoproteins or storage as lipid droplets. SFA can be released
from lipid droplets via macrolipophagy (Fig. 1A). Multiple mech-
anisms are concurrently operative to produce liver injury in
hepatocytes overwhelmed by SFA, primarily from adipocyte
lipolysis, and free cholesterol from de novo synthesis [1,2]. These
lipids, and in particular SFA, can activate a variety of intracellular
responses resulting in lipotoxic stress in the endoplasmic
reticulum (ER) and mitochondria, respectively. As a consequence,
apoptosis occurs which represents a key pathogenic feature of
NASH. Metabolic stress from lipids has also been linked to
macrolipophagy dysfunction, presumably at the level of
autophagosome-lysosome fusion [3]. Whether this promotes
additional lipid accumulation or increased lipolysis in NASH
remains to be addressed.Journal of Hepatology 20
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(A.J. Sanyal).Continuous excessive availability of SFA likely generates lipid
intermediates that will shift normal triacylglyceride formation
towards induction of ER stress with accumulation of unfolded
or misfolded proteins in the ER [4]. This perturbation promotes
a state of oxidative stress and triggers an evolutionary conserved
adaptive response activating signaling pathways that result in
translational arrest and degradation of proteins and production
of antioxidants to allow recovery and cell survival (Fig. 1B). This
adaptive response is activated by at least three ER stress sensors,
activating transcription factor 6 (ATF6), inositol requiring enzyme
1 (IRE1), and PKR-like ER kinase (PERK), respectively. Failure to
upregulate activating transcription factor 4 (ATF4) and efﬁciently
degrade proteins in response to activating X-box protein 1 (XBP1)
despite translational arrest of proteins synthesis via eukaryotic
initiation factor 2a (eIF2a) may identify NASH patients at partic-
ular risk to progress to cirrhosis due to insufﬁcient degradation of
unfolded proteins [1]. It remains to be determined whether the
antioxidant response via combined activation of ATF4 and the
transcription factor NRF2 is impaired in patients with NASH [5].
Once the adaptive response machinery fails and the ER stress
continues, then the alarm response is activated and promotes
apoptosis (Fig. 1C). IRE1, PERK, and ATF6 all converge at the level
of C/EBP homologous protein (CHOP) which forms a heteromeric
complex with c-Jun to positively regulate p53 upregulated
modulator of apoptosis (PUMA) expressionwith subsequent B-cell
lymphoma 2-associated X protein (Bax) activation [6]. As a conse-
quence, mitochondrial membrane channel formation results in
the release of cytochrome c into the cytosol, promoting activation
of downstream effector caspase-3 and -7, proteases that dismantle
the cell and cause cell death by apoptosis. IRE1 can also bind tumor
necrosis factor receptor-associated factor 2 (TRAF2) to activate
apoptosis signal-regulating kinase 1 (ASK1) and downstream Jun
N-terminal kinase (JNK) to facilitate formation of the c-Jun/CHOP
heteromeric complex [7]. CHOP in addition upregulates death
receptors (e.g. DR5) that sensitize hepatocytes to circulating death
ligands. Mitochondrial dysfunction may be further augmented by
stress-induced release of calcium by the ER.
The toll-like receptor 4 (TLR4) is a pattern-recognition recep-
tor that activates a proinﬂammatory-signaling pathway in
response to SFAs. This pathway (Fig. 1D) is initiated by recruiting
adaptor molecules Toll/IL-1 receptor domain containing adaptor
protein (TIRAP) and myeloid differentiation factor 88 (MyD88)
that ultimately leads to activation of nuclear factor jB with pro-
duction of tumor necrosis factors a (TNFa) [8]. Binding of TNFa to
the TNF receptor forms a complex consisting of TNF receptor12 vol. 56 j 291–293
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Fig. 1. Lipotoxicity in NASH. (A) Flux and utilization of saturated fatty acids in the liver. (B) The adaptive response to ER stress in NASH. (C) The alarm response to ER stress
in NASH. (D) Toll-like receptor 4 (TLR4) and tumor necrosis factor receptor (TNFR) signaling in NASH. (E) Death receptor signaling in NASH. Chol, cholesterol; SFA, saturated
fatty acid; VLDL, very low density lipoprotein; ER, endoplasmic reticulum; ROS, reactive oxygen species; IRE1, inositol-requiring enzyme 1; JNK, c-Jun N-terminal kinase;
PUMA, p53 upregulated modulator of apoptosis; PERK, PKR-like endoplasmic reticulum kinase; eIF2a, alpha subunit of the eukaryotic initiation factor 2; ATF4/6, activating
transcription factor 4/6; CHOP, CCAAT/enhancer-binding homologous protein; Bim, Bcl-2 protein family member; DR5, death receptor 5. NASH, non-alcoholic fatty liver
disease; XBP1, X-box protein 1; IP3, inositol triphosphate activated calcium channel; TRAF2, tumor necrosis factor receptor-associated factor 2; ASK1, apoptosis signal-
regulating kinase 1; CHOP, C/EBP homologous protein; Bax, B-cell lymphoma 2-associated X protein; PUMA, p53 upregulated modulator of apoptosis; TIRAP, Toll/IL-1
receptor domain containing adaptor protein; MyD88, myeloid differentiation factor 88; IRAK, interleukin 1 receptor associated kinase; TRAF2/6, TNF receptor associated
factor 2/6; NEMO, NFjB essential modulator; TRADD, TNF receptor associated death domain protein; RIP, receptor interacting protein; FADD, Fas-associated protein with
death domain; BID, pro-apoptotic BCL-2 interacting domain; FoxO3a, forkhead box-containing protein, class O member 3a; TNFa, tumor necrosis factor a; NFjB, nuclear
factor j B; NRF2, NF-E2 related factor 2.
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associated death domain protein (TRADD), TNF receptor associ-
ated factor 2 (TRAF2), and receptor interacting protein (RIP). This
complex activates a pro-apoptotic ASK1/JNK pathway that ulti-
mately results in Bim activation and mitochondrial dysfunction.
Activation of forkhead box-containing protein, class 0, member
3a (FoxO3a) mediated by SFA-stimulated protein phosphatase
2a activity may work in concert with JNK to activate Bim [9].
The TRADD/TRAF2/RIP complex may be internalized and after
recruiting Fas-associated protein with death domain (FADD),
the mitochondrial ampliﬁcation loop is activated by caspase 8.
Lysosomal involvement in apoptosis has also been described in
patients with NASH (Fig. 1D). Upon cytosol-to-lysosome translo-
cation of Bax and lysosomal membrane permeabilization, cathep-
sin B is released into cytosol with subsequent increased
production of TNFa via activation of the NF-jB pathway [10].
Under physiological conditions, hepatocytes are relatively resis-
tant to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) and Fas cytotoxicity. However, in patients with NASH
hepatocytes appear to be sensitized and hepatic upregulation of
the TRAIL receptor DR5 was observed (Fig. 1E).Conﬂict of interest
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